On October 14, 2009
J&J Q3: Duragesic Sales Down 20% Following Fentanyl Patch Death Warnings
Doctors may finally be getting the message about dangers associated with fentanyl patches, if Johnson & Johnson’s Q3 2009 earnings are any indication. While J&J saw revenues fall 5.3 percent to $15 billion and net income rise 22.2 percent to $3.3 billion, the numbers were much more dramatic on the line for Duragesic, J&J’s fentanyl patch.
0 Comments